Pfizer, Inc. (NYSE: PFE) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the full approval of Paxlovid, its antiviral pill for Covid-19. The drug currently has emergency use authorization (EUA) for the treatment of mild-to-moderate Covid-19. Albert Bourla, the Chairman and CEO of Pfizer, said, “Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce Paxlovid as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status.
https://www.tipranks.com/news/pfizer-has-big-plans-for-paxlovid?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 7 2022 まで 8 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2021 まで 8 2022 Pfizerのチャートをもっと見るにはこちらをクリック